Blog

UC DAVIS Researchers hone in on Angelman Syndrome Treatment

FAST (Foundation for Angelman Syndrome Therapeutics) has funded two research labs at the University of California, Davis (UC Davis) to further investigation into gene editing for Angelman Syndrome. One funded project continues the evaluation of Artificial Transcription Factors (ATFs or Zinc Fingers) for the treatment of Angelman Syndrome (AS) in Dr. David Segal’s  laboratory (pictured

Read More >

5.8 Million Steps Closer To A Cure

How FAST Is Changing The Landscape Of Angelman Research When you set out to cure an ‘incurable’ genetic disorder, you need three things: a comprehensive, well thought out plan; a dedicated and passionate community; and sufficient, often substantial funding. With a grant from the Marnier Lapostolle Foundation of $5.8 million, the Foundation for Angelman Syndrome

Read More >

Ketone ester supplementation Update

Ketone ester supplementation attenuates seizure activity, and improves behavior and hippocampal synaptic plasticity in an Angelman syndrome mouse model

FAST-Funded Research Leads To $1.1 Million Grant

Additional Gene Therapy Approach For Angelman Syndrome Explored By Paula Evans The Foundation for Angelman Syndrome Therapeutics (FAST) is delighted to announce that research FAST has funded, through the support of our donors, has secured a $1.1 Million grant from the California Institute for Regenerative Medicine, to develop an additional gene therapy approach for the

Read More >

Towards Therapeutics – The FIRE Team Series, Part II

RDr. Dindot’s 3 goals, which have been the focus of his AS research through the FIRE initiative, are;
Mechanisms regulating imprinting of UBE3A in neurons, Identification of new therapeutic potentials for AS using high
throughput assays and Generation of new animal models of AS.

Maggie Linton Show

Dr Allyson Berent, the Chief Science Officer at the Foundation for Angelman Syndrome Therapeutics, talks with popular radio journalist Maggie Linton about Angelman Syndrome awareness and the future therapeutics and clinical trials on Sirius XM Urban View.

A Message To All Of Our Angelman STARS

Help Ovid Therapeutics Color Our World Beautiful! An Announcement from Ovid Therapeutics Ovid Therapeutics is working towards initiating its phase II study of OV101 in Angelman Syndrome adults. One step of the process is to name the study and develop a study logo. The study will be named the STARS clinical trial, which is an

Read More >

Towards Therapeutics – The FIRE Team Series, Part I

Edwin Weeber, Ph.D. is a Professor in the Department of Molecular Pharmacology and Physiology and the Chief Scientific Officer at the University of South Florida Health Byrd Alzheimer Institute. Dr. Weeber also serves on the Foundation for Angelman Syndrome Therapeutic’s (FAST) Scientific Advisory Board and the FAST Integrative Research Environment (FIRE) Initiative.   The FIRE

Read More >

^